FY2025 Earnings Forecast for ANRO Issued By Chardan Capital

Key Points

• Chardan Capital projects Alto Neuroscience's FY2025 earnings per share (EPS) at ($2.45), slightly improving from the market consensus of ($2.54).
• HC Wainwright maintains a "buy" rating with a target price of $10.00, while the average target across analysts is $9.80 for the stock.
• Alto Neuroscience's stock opened at $4.44 and has experienced significant volatility, with a one-year low of $1.60 and a high of $15.04.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Tuesday, September 30th. Chardan Capital analyst R. Li expects that the company will post earnings of ($2.45) per share for the year. Chardan Capital has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience's FY2026 earnings at ($1.80) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Alto Neuroscience in a research report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.80.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.44 on Friday. Alto Neuroscience has a one year low of $1.60 and a one year high of $15.04. The firm has a 50-day simple moving average of $3.60 and a two-hundred day simple moving average of $2.84. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The firm has a market cap of $120.10 million, a price-to-earnings ratio of -1.86 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Armistice Capital LLC boosted its position in Alto Neuroscience by 1.5% in the second quarter. Armistice Capital LLC now owns 1,624,000 shares of the company's stock valued at $3,573,000 after buying an additional 24,000 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company's stock worth $2,062,000 after purchasing an additional 84,417 shares during the last quarter. AWM Investment Company Inc. boosted its holdings in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock valued at $1,948,000 after purchasing an additional 214,153 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $613,000. Finally, Nuveen LLC acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at about $302,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.